News
Nicotinamide riboside — also called niagen — supports many aspects of healthy aging. This article reviews nicotinamide riboside, its benefits, side effects and dosage.
Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine ...
Randomized to receive either 500 mg of nicotinamide riboside (Niagen) twice daily or placebo for 52 weeks, participants had follow-up assessments at five time points in a one-year period.
5d
GlobalData on MSNNiagen Bioscience signs exclusive licence deal for PD therapyNiagen Bioscience can either commercialise the drug candidate independently or sublicense to a strategic pharmaceutical ...
Investing.com -- Niagen Bioscience Inc (NASDAQ: NAGE) stock rose 2% after the company announced an exclusive worldwide commercial license agreement with Norway’s Haukeland University Hospital to ...
6d
InvestorsHub on MSNNiagen Bioscience Shares Climb Following Exclusive License for Parkinson’s TherapyNiagen Bioscience Inc. (NASDAQ:NAGE) saw its stock rise 2% after securing an exclusive global commercial license from Norway’s Haukeland University Hospital to develop its nicotinamide riboside ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results